‘Allogeneic marrow transplantation in children with acute leukemia: a practice whose time has gone’: twenty years later

Pinkel, Donald

doi:10.1038/leu.2009.132

Cited by 12 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allogeneic he-matopoietic stem-cell transplantation (HSCT) can effectively induce immunologic antileukemic control in children with ALL by means of the graftversus-leukemia effect. 8,9 Thus, in 2003, the Berlin-Frankfurt-Muenster (BFM) study group initiated the prospective international multicenter ALL-SCT-BFM 2003 (Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia) trial of allogeneic HSCT for children with ALL and indications for HSCT according to first-line and relapse chemotherapy protocols during first, second, or subsequent complete remissions (CRs). Only 20% to 25% of children with indications for allogeneic HSCT have HLAmatched sibling donors (MSDs), but the availability JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T of volunteer HLA-matched unrelated donors (MUDs) has increased transplantation rates over recent decades.…”

Section: Introductionmentioning

confidence: 99%

Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors—The ALL-SCT-BFM-2003 Trial

Peters

Schrappe

Stackelberg

et al. 2015

JCO

196

177

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors—The ALL-SCT-BFM-2003 Trial

Peters

Schrappe

Stackelberg

et al. 2015

JCO

196

177

View full text Add to dashboard Cite

show abstract

“…The standard risk (SR) group was composed of AML in first CR1, ALL in CR1 and CR2, aplastic anemia and hematological non-malignancies. [27][28][29] The high-risk (HR) group was defined by AML4CR1, ALL4CR2, lymphomas and all malignant diseases in PR, progressive evolution or relapse. As part of current practice, patients and donors gave their approval for use of their data for research purposes.…”

Section: Patients and Methods Patientsmentioning

confidence: 99%

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution

Brissot

Rialland

Cahu

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

International audienceAllogeneic stem cell transplantation (allo-SCT) has become an essential component of the treatment for a variety of diseases in pediatric patients. During the past decades, advances in the transplant technology, availability of hematopoietic stem cells and supportive care not only have resulted in improved outcomes, but also have expanded the transplant options. However, these features have been studied mainly in adult populations. This investigation analyzed changes in patient profile, transplantation, graft characteristics and outcome among 250 children and adolescent patients who received allo-SCT in a single center between 1983 and 2010. In the 2000–2010, compared with the 1983–1999 period, a significantly higher 5-year overall survival (64% versus 52%, P=0.03) was observed together with a significant decrease of non-relapse mortality (27% versus 9%, P=0.0002). The progression-free survival was comparable between the two periods (49% versus 57%; P=0.17). The 5-year cumulative incidence of relapse was 24% between 1983 and 1999, and 34% between 2000 and 2010 (P=0.08). Major advances in supportive care practice have been made over the past decade, resulting in a significant survival benefit for the pediatric population undergoing allo-SCT. However, post-transplant relapse remains the leading cause of failure of this therapeutic approach, and preventing relapse represents a major challenge toda

show abstract

“…Unfortunately, even in this setting with access to novel therapies, a subgroup of high‐risk patients still relapse and ultimately die . Allogeneic HSCT is the standard approach for this high‐risk subset of patients who need additional therapeutic approaches …”

Section: Introductionmentioning

confidence: 99%

Early bacterial and fungal infection in children receiving allogeneic stem cell transplantation for acute lymphoblastic leukemia in Argentina

Gómez

Fynn

Fernanda

et al. 2017

Pediatric Transplantation

View full text Add to dashboard Cite

Infections are important complications associated with allogeneic HSCT. Describing infection rates in low- and middle-income countries provides data to infer efficacy of supportive care practices in these settings. In this retrospective cohort study, we included patients (age ≤ 18 years) who underwent a first allogeneic HSCT for ALL in a single center in Argentina between 1998 and 2016. The primary outcome was sterile site bacterial infection. Secondary outcomes were proven or probable invasive fungal infection, TRM, and infectious deaths. There were 68 allogeneic HSCT recipients with ALL included in this analysis. Overall, 17 (25.0%) experienced at least one sterile site bacterial infection and 10 (14.7%) experienced at least one proven or probable invasive fungal infection. The TRM rate was 19.1%, and 3 (4.4%) patients died of infection. In a middle-income country center in Argentina, pediatric allogeneic HSCT infection rates, TRM, and infection-related mortality were comparable to high-income countries. These data support continuation of allogeneic HSCT programs in similar resource-limited settings provided that adequate supportive care and monitoring of outcomes can be performed.

show abstract

‘Allogeneic marrow transplantation in children with acute leukemia: a practice whose time has gone’: twenty years later

Cited by 12 publications

References 34 publications

Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors—The ALL-SCT-BFM-2003 Trial

Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors—The ALL-SCT-BFM-2003 Trial

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution

Early bacterial and fungal infection in children receiving allogeneic stem cell transplantation for acute lymphoblastic leukemia in Argentina

Contact Info

Product

Resources

About